For Prevention and Quality of Life Issues.

1: Multiple Sclerosis: At the University of Michigan Medical School, researchers found that damage to the myelin sheath(as in diabetic neuropathy, multiple sclerosis and amyotropic lateral sclerosis) when stimulated by IGF-1(Somatomedin C) helped the nerves reconnect. October 28, 1997.

2: Congestive Heart Failure: Dr. Marc Y Donath of the Jean Hailes' Foundation in Clayton, Australia, reported that acute administration of IGF-1 in eight congestive heart failure patients improved cardiac function by afterload reduction and possibly through a positive inotropic effect.   In this randomized, double-blind, crossover trial, IGF-1 was associated with a 27% rise in cardiac index, a 21% boost in stroke volume index, a 28% reduction in systemic vascular resistance, a 25% decline in pulmonary artery wedge pressure, and a 33% drop in right atrial pressure. August 28, 1997.

3: Fibromyalgia: Patients with fibromyalgia may be the largest population of growth hormone-deficient individuals according to a presentation at the annual meeting of the Endocrine Society in Minneapolis Minnesota. Based upon intriguing evidence that deficient growth hormone secretion is common among fibromyalgia patients.   The connection between fibromyalgia and GH deficiency syndrome is that they share many clinical features, including muscle weakness, reduced exercise capacity, chronic fatigue, and feeling of social isolation.  In an earlier study, they found that 30-40% of fibromyalgia patients had low IGF-1 levels and that they did not respond to provocative testing.

4: Diabetes: On Wednesday June 17, 1998, Longevity News Network announced, "New Natural Anti-Aging Technologies May Be Reducing Diabetic Insulin Dependency". This was based upon clinical observation of patients with diabetes who began a course of supplementation with SYMBIOTROPIN found in Medi-GH.